Skip to main content
SpringerLink
Log in
Book cover

Studies on Pediatric Disorders pp 115–135Cite as

Urinary L-Type Fatty Acid-Binding Protein as a New Renal Biomarker

  • Chapter
  • First Online:

  • 833 Accesses

Abstract

Fatty acid-binding proteins (FABPs) are a group of intracellular proteins of 14 kDa, belonging to the lipocalin family. FABPs play a key role in the binding and trafficking of fatty acids and some other hydrophobic molecules. In the human kidney, liver-type FABP (L-FABP) is expressed in the proximal tubule. L-FABP expression and secretion into urine is increased during tubulointerstitial damage in the kidney. Our research laboratory has developed L-FABP ELISA kit for diagnostic use in Japan. This chapter provides a brief summary of the urinary L-FABP monitoring with particular emphasis on its important roles in recent clinical studies (e.g., diabetic nephropathy, non-diabetic nephropathy, contrast-induced acute kidney injury, septic shock, kidney transplant, pediatric acute kidney injury).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

ACE:

Angiotensin converting enzyme

ADPKD:

Autosomal dominant polycystic kidney disease

AER:

Albumin excretion rate

AKI:

Acute kidney injury

AKIN:

Acute Kidney Injury Network

APACHE:

Acute physiology and chronic health evaluation

ARB:

Angiotensin II receptor blocker

ARF:

Acute renal failure

AUC:

Area under the curve

BSA:

Bovine serum albumin

CCD:

Charge coupled devices

CI-AKI:

Contrast-induced acute kidney injury

CKD:

Chronic kidney disease

CPB:

Cardiopulmonary bypass

DN:

Diabetic nephropathy

ELISA:

Enzyme-linked immunosorbent assay

FABP:

Fatty acid-binding protein

FFA:

Free fatty acid

FGS:

Focal glomerulosclerosis

HIF:

Hypoxia-inducible factor

HNF:

Hepatocyte nuclear factor

ICU:

Intensive care unit

IL-18:

Interleukin-18

IVD:

In vitro diagnostics

KDIGO:

Kidney Disease Improving Global Outcomes

KIM-1:

Kidney injury molecule-1

LDL:

Low-density lipoprotein

L-FABP:

Liver-type fatty acid-binding protein

MCNS:

Minimal change nephrotic syndrome

MG:

Microglobulin

NAG:

N-acetyl-β-d-glucosaminidase

NGAL:

Neutrophil gelatinase-associated lipocalin

8-OHdG:

8-Hydroxydeoxyguanosine

pAKI:

Pediatric acute kidney injury

PMX-F:

Polymyxin B-immobilized fiber

PPAR:

Peroxisome proliferator-activated receptor

ROC:

Receiver operating characteristic

UAE:

Urinary albumin excretion

References

  1. Hewitt MH, Dear J, Star RA (2004) Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol 15:1677–1689

    Article  PubMed  Google Scholar 

  2. Veerkamp JH, Peeters RA, Maatman RG (1991) Structural and functional features of different types of cytoplasmic fatty acid binding proteins. Biochim Biophys Acta 1081:1–24

    Article  CAS  PubMed  Google Scholar 

  3. Chmurznska A (2006) The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet 47:39–48

    Article  Google Scholar 

  4. Nakamura K, Ito K, Kato U, Sugaya T, Kubo Y, Tsuji A (2008) L-type fatty acid binding protein transgenic mouse as a novel tool to explore cytotoxicity to renal proximal tubules. Drug Metab Pharmacokinet 23:271–278

    Article  CAS  PubMed  Google Scholar 

  5. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Kimura K (2005) Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med 145:125–133

    Article  CAS  PubMed  Google Scholar 

  6. Kamijo A, Sugaya T, Hikawa A, Okada M, Okumura F, Yamanouchi M, Honda A, Okabe M, Fujino T, Hirata Y, Omata M, Kaneko R, Fujii H, Fukamizu A, Kimura K (2004) Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 165:1243–1255

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hase K, Kaneko T, Hirata Y, Goto A, Fujita T, Omata M (2002) Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int 62:1628–1637

    Article  CAS  PubMed  Google Scholar 

  8. Arici M, Chana R, Lewington A, Brown J, Brunskill NK (2003) Stimulation of proximal tubular cell apoptosis by albumin-bound fatty acids mediated by peroxisome proliferators activated receptor gamma. J Am Soc Nephrol 14:17–27

    Article  CAS  PubMed  Google Scholar 

  9. Thomas ME, Schreiner GF (1993) Contribution of proteinuria to progressive renal injury: consequences of tubular uptake of fatty acid bearing albumin. Am J Nephrol 13:385–389

    Article  CAS  PubMed  Google Scholar 

  10. Thomas ME, Morrison AR, Schreiner GF (1995) Metabolic effects of fatty acid bearing albumin on a proximal tubule cell line. Am J Physiol 268:F1177–F1184

    CAS  PubMed  Google Scholar 

  11. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H (2005) Effect of pitavastatin on urinary liver-type fatty acid-protein levels in patients with early diabetic nephropathy. Diabetes Care 28:2728–2732

    Article  CAS  PubMed  Google Scholar 

  12. Ishimitsu T, Ohta S, Saito M, Teranishi M, Inada H, Yoshii M, Minami J, Ono H, Hikawa A, Shibata N, Sugaya T, Kamijo A, Kimura K, Ohrui M, Matsuoka H (2005) Urinary excretion of liver fatty acid-binding protein in health-check participants. Clin Exp Nephrol 9:34–39

    Article  CAS  PubMed  Google Scholar 

  13. Sasaki H, Kamijo-Ikemori A, Sugaya T, Yamashita K, Yokoyama T, Koike J, Sato T, Yasuda T, Kimura K (2009) Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy. Nephron Clin Pract 112:c148–c156

    Article  CAS  PubMed  Google Scholar 

  14. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Hayakawa H, Takagi M, Tabei F, Sugimoto T, Mise N, Omata M, Kimura K (2006) Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem 284:175–182

    Article  CAS  PubMed  Google Scholar 

  15. Nakamura T, Fujiwara N, Sugaya T, Ueda Y, Koide H (2009) Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy. Metabolism 58:1185–1190

    Article  CAS  PubMed  Google Scholar 

  16. von Eynatten M, Baumann M, Heemann U, Zdunek D, Hess G, Nawroth PP, Bierhaus A, Humpert PM (2010) Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes. Eur J Clin Invest 40:95–102

    Article  Google Scholar 

  17. Araki SI, Haneda M, Koya D, Sugaya T, Isshiki K, Kume S, Kashiwagi A, Uzu T, Maegawa H (2013) Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care 36:1248–1253

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Suzuki K, Murata H, Babazono T, Iwamoto Y (2005) Clinical significance of urinary liver-type fatty acid-binding protein in patients with diabetic nephropathy. Diabetes Care 28:2038–2039

    Article  PubMed  Google Scholar 

  19. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H (2006) Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. Diabetes Metab Res Rev 22:385–389

    Article  CAS  PubMed  Google Scholar 

  20. Kamijo-Ikemori A, Sugaya T, Yasuda T, Kawata T, Ota A, Tatsunami S, Kaise R, Ishimitsu T, Tanaka Y, Kimura K (2011) Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care 34:691–696

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hikawa A, Hirano N, Hirata Y, Goto A, Omata M (2004) Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 143:23–30

    Article  CAS  PubMed  Google Scholar 

  22. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H (2005) Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease. Am J Med Sci 330:161–165

    Article  PubMed  Google Scholar 

  23. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H (2006) Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low density lipoprotein apheresis. Clin Nephrol 65:1–6

    Article  CAS  PubMed  Google Scholar 

  24. Matsui K, Kamijo-Ikemori A, Sugaya T, Yasuda T, Kimura K (2011) Usefulness of urinary biomarkers in early detection of acute kidney injury after cardiac surgery in adults. Circ J 76:213–220

    Article  PubMed  Google Scholar 

  25. Portilla D, Dent C, Sugaya T, Nagothu KK, Kundi I, Moore P, Noiri E, Devarajan P (2008) Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int 73:465–472

    Article  CAS  PubMed  Google Scholar 

  26. Matsui K, Kamijo-Ikemori A, Hara M, Sugaya T, Kodama T, Fujitani S, Taira Y, Yasuda T, Kimura K (2011) Clinical significance of tubular and podocyte biomarkers in acute kidney injury. Clin Exp Nephrol 15:220–225

    Article  CAS  PubMed  Google Scholar 

  27. Doi K, Katagiri D, Negishi K, Hasegawa S, Hamasaki Y, Fujita T, Matsubara T, Ishii T, Yahagi N, Sugaya T, Noiri E (2012) Mild elevation of urinary biomarkers in prerenal acute kidney injury. Kidney Int 82:1114–1120

    Article  CAS  PubMed  Google Scholar 

  28. Cho E, Yang HN, Jo SK, Cho WY, Kim HK (2013) The role of urinary liver-type fatty acid-binding protein in critically ill patients. J Korean Med Sci 28:100–105

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Nakamura T, Sugaya T, Node K, Ueda Y, Koide H (2006) Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am J Kidney Dis 47:439–444

    Article  CAS  PubMed  Google Scholar 

  30. Manabe K, Kamihata H, Motohiro M, Senoo T, Yoshida S, Iwasaka T (2012) Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury. Eur J Clin Invest 42:557–563

    Article  CAS  PubMed  Google Scholar 

  31. Uriu K, Osajima A, Hiroshige K, Watanabe H, Aibara K, Inada Y, Segawa K, Anai H, Takagi I, Ito A, Kamuchi M, Kaizu K (2002) Endotoxin removal by direct hemoperfusion with an adsorbent column using polymyxin B-immobilized fiber ameliorates systemic circulatory disturbance in patients with septic shock. Am J Kidney Dis 39:937–947

    Article  CAS  PubMed  Google Scholar 

  32. Shoji H (2003) Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 7:108–114

    Article  CAS  PubMed  Google Scholar 

  33. Ono S, Tsujimoto H, Matsumoto A, Ikuta S, Kinoshita M, Mochizuki H (2004) Modulation of human leukocyte antigen DR on monocytes and CD 16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin B-immobilized fiber. Am J Surg 188:150–156

    Article  CAS  PubMed  Google Scholar 

  34. Nakamura T, Sugaya T, Koide H (2009) Urinary liver-type fatty acid-binding protein in septic shock: effect of polymyxin B-immobilized fiber hemoperfusion. Shock 31:454–459

    Article  CAS  PubMed  Google Scholar 

  35. Doi K, Noiri E, Sugaya T (2010) Urinary l-type fatty acid-binding protein as a new renal biomarker in critical care. Curr Opin Crit Care 16:545–549

    Article  PubMed  Google Scholar 

  36. Yamamoto T, Noiri E, Ono Y, Doi K, Negishi K, Kamijo A, Kimura K, Fujita T, Kinukawa T, Taniguchi H, Nakamura K, Goto M, Shinozaki N, Ohshima S, Sugaya T (2007) Renal L-type fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol 18:2894–2902

    Article  CAS  PubMed  Google Scholar 

  37. Tsukahara H, Sugaya T, Hayakawa K, Mori Y, Hiraoka M, Hata A, Mayumi M (2005) Quantification of L-type fatty acid binding protein in the urine of preterm neonates. Early Hum Dev 81:643–646

    Article  CAS  PubMed  Google Scholar 

  38. Ivanisevic I, Peco-Antric A, Vullcevic I, Hercog D, Milovanovic V, Kotur-Stevuljevic J, Stefanovic A, Kocev N (2013) L-FABP can be an early marker of acute kidney injury in children. Pediatr Nephrol 28:963–969

    Article  PubMed  Google Scholar 

  39. Schiffl H, Lang SM (2013) Urinary biomarkers and acute kidney injury in children: the long road to clinical application. Pediatr Nephrol 28:837–842

    Article  PubMed  Google Scholar 

  40. Moore E, Bellomo R, Nichol A (2010) Biomarkers of acute kidney injury in anesthesia, intensive care and major surgery: from the bench to clinical research to clinical practice. Minerva Anestesiol 76:425–440

    CAS  PubMed  Google Scholar 

  41. Doi K, Negishi K, Ishizu T, Katagiri D, Fujita T, Matsubara T, Yahagi N, Sugaya T, Noiri E (2011) Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit. Crit Care Med 39:2464–2469

    Article  CAS  PubMed  Google Scholar 

  42. Nakamura T, Sugaya T, Koide H (2006) Cigarette smoking affects urinary liver-type fatty acid-binding protein concentration in patients with early diabetic nephropathy. Diabetes Care 29:1717

    Article  PubMed  Google Scholar 

  43. Nakamura T, Sugaya T, Koide H (2007) Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure. Diabetologia 50:490–492

    Article  CAS  PubMed  Google Scholar 

  44. Nakamura T, Inoue T, Fujiwara N, Kawagoe Y, Sugaya T, Ueda Y, Koide H, Node K (2008) Additional renoprotective effects of azelinidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy. Clin Nephrol 70:385–392

    Article  CAS  PubMed  Google Scholar 

  45. Nakamura T, Fujiwara N, Sato E, Ueda Y, Sugaya T, Koide H (2010) Renoprotective effects of various angiotensin II receptor blockers in patients with early-stage diabetic nephropathy. Kidney Blood Press Res 33:213–220

    Article  CAS  PubMed  Google Scholar 

  46. Nielsen SE, Sugaya T, Tarnow L, Lajer M, Schjoedt KJ, Astrup AS, Baba T, Parving HH, Rossing P (2009) Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care 32:1684–1688

    Article  PubMed Central  PubMed  Google Scholar 

  47. Nielsen SE, Sugaya T, Hovind P, Baba T, Parving HH, Rossing P (2010) Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care 33:1320–1324

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  48. Panduru NM, Forsblom C, Saraheimo M, Thorn L, Bierhaus A, Humpert PM, Groop PH, on behalf of the FinnDiane Study Group (2013) Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 36(7):2077–2083

    Article  CAS  PubMed  Google Scholar 

  49. Nakamura T, Sugaya T, Ebihara I, Koide H (2005) Urinary liver-type fatty acid-binding protein: discrimination between IgA nephropathy and thin basement membrane nephropathy. Am J Nephrol 25:447–450

    Article  CAS  PubMed  Google Scholar 

  50. Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Node K (2007) Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy. Am J Hypertens 20:1195–1201

    CAS  PubMed  Google Scholar 

  51. Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Inoue T, Node K (2006) Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. Am J Nephrol 26:82–86

    Article  CAS  PubMed  Google Scholar 

  52. Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H (2006) Effect of erythropoietin on urinary liver-type fatty-acid-binding protein in patients with chronic renal failure and anemia. Am J Nephrol 26:276–280

    Article  CAS  PubMed  Google Scholar 

  53. Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K (2007) Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 333:321–326

    Article  PubMed  Google Scholar 

  54. Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Node K (2008) Renoprotective effect of telmisartan in patients with chronic kidney disease. Clin Exp Hypertens 30:662–672

    Article  CAS  PubMed  Google Scholar 

  55. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Sugaya T, Yamagishi S, Yamada S, Koide H (2010) Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease. Am J Med Sci 339:157–163

    Article  PubMed  Google Scholar 

  56. Nakamura T, Fujiwara N, Kawagoe Y, Sugaya T, Ueda Y, Koide H (2010) Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease. Eur J Clin Invest 40:790–796

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Dr. Kenjiro Kimura and Dr. Atsuko Kamijo-Ikemori (Department of Nephrology and Hypertension, Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan), Dr. Yasuhiko Tomino and Dr. Yusuke Suzuki (Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan) for scientific encouragement and helpful discussions.

Author information

Authors and Affiliations

  1. CMIC Holdings Co. Ltd., Tokyo, 113-0034, Japan

    Tsuyoshi Oikawa Ph.D. & Takeshi Sugaya Ph.D.

  2. Department of Nephrology and Hypertension, Internal Medicine, St. Marianna University School of Medicine, Kanagawa, 216-8511, Japan

    Takeshi Sugaya Ph.D.

Authors
  1. Tsuyoshi Oikawa Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeshi Sugaya Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takeshi Sugaya Ph.D. .

Editor information

Editors and Affiliations

  1. Dentistry and Pharmaceutical Sciences Department of Pediatrics, Okayama University Graduate School of Medicine, Okayama, Japan

    Hirokazu Tsukahara

  2. Department of Pediatrics, Kansai Medical University, Osaka, Japan

    Kazunari Kaneko

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Oikawa, T., Sugaya, T. (2014). Urinary L-Type Fatty Acid-Binding Protein as a New Renal Biomarker. In: Tsukahara, H., Kaneko, K. (eds) Studies on Pediatric Disorders. Oxidative Stress in Applied Basic Research and Clinical Practice. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0679-6_7

Download citation

Publish with us

Policies and ethics

Search

Navigation